Document is current
Any future updates will be listed below
-
Authors
Kobayashi, Noritoshi
Yabushita, Yasuhiro
Mori, Ryutaro
Takahashi, Tomoaki
Miyake, Kentaro
Sawada, Yu
Homma, Yuki
Matsuyama, Ryusei
Okubo, Naoki
Katsuta, Eriko
Kubota, Kensuke
Yamanaka, Shoji
Ichikawa, Yasushi
Endo, Itaru
- License Information
-
More Information
Article History
Received: 24 March 2025
Accepted: 8 October 2025
First Online: 13 November 2025
Declarations
:
: Noritoshi Kobayashi received an honorarium from Novartis.K.K., Teijin Pharma, Teijin Healthcare, EA Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, Yakuruto Honsha, MSD, and PD Radiopharma (suc-cessor to the radiopharmaceutical business of Fujifilm Toyama Chemical Co., Ltd.). Research expenses from company Novartis.K.K. The authors declare no conflicts of interest. The funder had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or the decision to publish the results.
: This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Yokohama City University Hospital (protocol code B140508029; date of approval: June 1 st, 2014). This study was registered with the Japanese Clinical Trials Registry (under UMIN000014039. ( ). The registration date was June 1, 2014. The patients provided written informed consent before enrollment in the study.
